TAX3503 三期随机对照试验:高危生化复发前列腺癌术后雄激素剥夺治疗联合或不联合多西他赛
TAX3503 是一项多中心三期随机试验,纳入前列腺切除术后高危生化复发患者,随机接受 18 个月 ADT 联合或不联合多西他赛(75 mg/m2 每 3 周,共 10 周期)。主要终点为睾酮恢复至非去势水平后的 PFS。结果显示联合多西他赛未带来有临床意义的 PFS 改善,3 级及以上不良事件更多。
要点
- ADT 联合多西他赛组 PFS 中位 26.2 个月 vs 24.7 个月,HR 0.80(95%CI 0.61-1.04)。
- 总生存 HR 0.51(95%CI 0.23-1.10),中位数未达到。
- 联合组 3 级及以上不良事件发生率 48.0% vs 10.8%。
核心结论
- 在高危生化复发前列腺癌患者中,ADT 联合多西他赛未显示出有意义的临床获益。
- 多西他赛的加入未影响睾酮恢复。
研究设计与样本
- 多中心三期随机对照试验,2007 年 9 月至 2011 年 5 月共随机 413 例患者。
- 入组标准包括前列腺切除术后单独或术后放疗后 PSA ≥1.0 ng/ml、PSA 倍增时间 ≤9 个月、CT 和骨扫描无转移。
- 干预为 ADT 18 个月联合或不联合多西他赛 75 mg/m2 每 3 周共 10 周期。
主要发现
- 中位随访 33.6 个月,260 例患者出现睾酮恢复,两组相似。
- 睾酮恢复人群中共 218 个事件,PFS 中位 26.2 vs 24.7 个月,HR 0.80(95%CI 0.61-1.04)。
- 意向治疗人群 OS 中位数未达到,HR 0.51(95%CI 0.23-1.10)。
- 联合组 3 级及以上不良事件发生率 48.0%,对照组 10.8%。
临床怎么用
- 对于前列腺切除术后高危生化复发患者,不推荐在 ADT 基础上常规联合多西他赛。
局限性
- 2012 年申办方停止支持研究,2013 年建立登记以保障主要终点,最终分析结合原始试验与登记数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No standard of care exists for patients with high-risk biochemical recurrence (BCR) after prostatectomy. OBJECTIVE: To evaluate whether addition of docetaxel to androgen deprivation therapy (ADT) improved progression-free survival (PFS) in high-risk BCR patients. DESIGN, SETTING, AND PARTICIPANTS: TAX3503 was a multicenter phase 3 trial that randomized patients with high-risk BCR to ADT for 18 mo ± docetaxel (75 mg/m2 q3w for ten cycles). Eligibility included prostate-specific antigen (PSA) ≥1.0 ng/ml after prostatectomy alone or after postoperative radiation therapy, PSA doubling time ≤9 mo, and absence of metastases on computed tomography and bone scintigraphy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was PFS following testosterone recovery to noncastrate levels (testosterone >50 ng/dl). Secondary endpoints included time to testosterone recovery, overall survival (OS), quality of life, and safety. RESULTS AND LIMITATIONS: Between September 2007 and May 2011, 413 patients were assigned to ADT ± docetaxel. In 2012, following completion of accrual and treatment, the sponsor withdrew support of the study, and in 2013, a registry was created to secure the primary endpoint. The final analysis included data from the original trial and registry. At a median follow-up of 33.6 mo, 260 patients demonstrated testosterone recovery, which occurred similarly between groups. ADT plus docetaxel trended toward a nonclinically meaningful improvement in PFS (median 26.2 vs 24.7 mo) for the testosterone-recovered population (218 events, hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.61-1.04) and in OS for the intention-to-treat population (medians not reached, HR 0.51, 95% CI 0.23-1.10). Grade ≥3 adverse events occurred more frequently in the ADT plus docetaxel group (48.0% vs 10.8%). CONCLUSIONS: TAX3503 did not demonstrate a meaningful benefit of adding docetaxel to ADT in patients with high-risk BCR. Testosterone recovery was unaffected by addition of docetaxel to ADT. PATIENT SUMMARY: Addition of docetaxel to androgen deprivation therapy did not meaningfully improve outcomes for men with high-risk biochemically recurrent prostate cancer.
引用
- Morris MJ, Mota JM, Lacuna K, et al. Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). Eur Urol Oncol. 2021. PMID: 34020931. doi:10.1016/j.euo.2021.04.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。